The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 12 , ISSUE 2 ( March-April, 2011 ) > List of Articles

RESEARCH ARTICLE

Serum and Saliva Levels of Cathepsin L in Patients with Acute Coronary Syndrome

Iraj Mirzaii-Dizgah, Esmail Riahi

Citation Information : Mirzaii-Dizgah I, Riahi E. Serum and Saliva Levels of Cathepsin L in Patients with Acute Coronary Syndrome. J Contemp Dent Pract 2011; 12 (2):114-119.

DOI: 10.5005/jp-journals-10024-1019

Published Online: 01-02-2012

Copyright Statement:  Copyright © 2011; The Author(s).


Abstract

Aim

Coronary artery disease (CAD) is the major cause of death nearly all over the world, and accurate and rapid diagnosis of CAD is of major medical and economic importance. The aim of this study was to evaluate the serum and saliva levels of cathepsin L in patients with acute coronary syndrome (ACS).

Materials and methods

In a cross-sectional study, 39 patients with ACS and 28 with controls were recruited to the study, and cathepsin L levels were measured in serum, resting saliva, and stimulated saliva obtained 12 and 24 h after the onset of ACS by ELISA method. Statistical analyses of Fisher's exact test, the Student's t-test or Kruskal-Wallis test were performed.

Results

Stimulated saliva cathepsin L levels in patients with ACS 12 hours but not 24 hours after admission showed significant decrease compared with that in control subjects. However, there were no significant differences in serum and unstimulted saliva cathepsin L levels between groups.

Conclusion

Serum and saliva levels of cathepsin L remain unchanged in patients with ACS and hence may not be a promising factor in CAD risk assessment.

Clinical significance

It seems that serum and saliva cathepsin L may not be a good biomarker for CHD.

Abbreviations

CAD: Coronary artery disease, ACS: Acute coronary syndrome, CHD: Coronary heart disease, EU: Emergency unit, MI: Myocardial infarction.

How to cite this article

Mirzaii-Dizgah I, Riahi E. Serum and Saliva Levels of Cathepsin L in Patients with Acute Coronary Syndrome. J Contemp Dent Pract 2011;12(2):114-119.


PDF Share
  1. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3 beta signaling. J Mol Med 2009;87:249-60.
  2. Cathepsin L in glioma progression: Comparison with cathepsin B. Cancer Detect Prev 2005;29:448-55.
  3. Arg/Lys aminopeptidase: A distinct prohormone processing pathway for the biosynthesis of peptide neurotransmitters and hormones. Biol Chem 2004;385:473-80.
  4. Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis and vascular cells. Atherosclerosis 2006;184: 302-11.
  5. Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts. Cancer Res 2004;64:8831-38.
  6. Apoptotic death of inflammatory cells in human atheroma. Arterioscler Thromb Vasc Biol 2001;21:1124-30.
  7. Legumain and cathepsin-L expression in human unstable carotid plaque. Atherosclerosis 208:83-89.
  8. Cathepsin L deficiency reduces diet-induced atherosclerosis in low-density lipoprotein receptor-knockout mice. Circulation 2007;115:2065-75.
  9. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie 92:1580-86.
  10. Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 2009;202:92-102.
  11. Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. Am J Cardiol 2009;103: 476-81.
  12. Dependence of cathepsin L-induced coronary endothelial dysfunction upon activation of NAD(P)H oxidase. Microvasc Res 2009;78:45-50.
  13. Alterations of serum cathepsins B and L in pre-eclampsia. Clin Chim Acta 2007;377:285-87.
  14. Cathepsins in human obesity: Changes in energy balance predominantly affect cathepsins in adipose tissue and in circulation. J Clin Endocrinol Metab 2010;95:1861-68.
  15. Serum cathepsin levels in coronary artery ectasia. Int J Cardiol 145:606-07.
  16. Plasma cathepsin L and its related pro/antiangiogenic factors play useful roles in predicting rich coronary collaterals in patients with coronary heart disease. J Int Med Res 38:1389-1403.
  17. IL-6/sIL-6R enhances cathepsin B and L production via caveolin-1-mediated JNK-AP-1 pathway in human gingival fibroblasts. J Cell Physiol 2008;217:423-32.
  18. Relationship of unstimulated whole saliva cortisol level with severity of oral dryness feeling in menopausal women. Australian Dental Journal 2011;56:171-74.
  19. Stimulated and unstimulated saliva progesterone in menopausal women with oral dryness feeling. Clin Oral Investig 2011.
  20. Relationship of stimulated saliva 17 beta-estradiol and oral dryness feeling in menopause. Maturitas 2009;62(2):197-99.
  21. Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal 2009;4(10):e521-e24.
  22. Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009;10(6):E001-E008.
  23. Saliva-based creatine kinase MB measurement as a potential point-of-care testing for detection of myocardial infarction. Clin Oral Invest 2011.
  24. Unstimulated whole saliva creatine phosphokinase in acute myocardial infarction. Oral Dis.
  25. Serum and stimulated whole saliva parathyroid hormone in menopausal women with oral dry feeling. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107(6):806-10.
  26. The composition of unstimulated whole saliva of healthy dental students. J Contemp Dent Pract May 1, 2006;7(2):104-11.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.